Ibogaine By David Dardashti today announced that preliminary research suggests ibogaine, a naturally occurring psychoactive alkaloid found in the root bark of the Tabernanthe iboga plant, may hold potential for treating Parkinson's disease. While some studies indicate ibogaine could impact the neurotransmitter systems involved in Parkinson's, the organization emphasizes the need for significantly more research to fully understand its effects and potential risks.
Parkinson's disease is a chronic and progressive neurodegenerative disorder that primarily affects dopamine-producing neurons in a specific area of the brain called the substantia nigra. This 1 dopamine deficiency leads to a range of motor symptoms, including:
-
Tremors: Involuntary shaking, often starting in the hands or fingers.
-
Rigidity: Stiffness in the limbs and trunk, making movement difficult.
-
Bradykinesia: Slowness of movement, affecting activities like walking, talking, and eating.
-
Postural Instability: Difficulty with balance and coordination, increasing the risk of falls.
Beyond motor symptoms, Parkinson's disease can also cause non-motor symptoms such as cognitive impairment, sleep disturbances, depression, and anxiety.
Ibogaine is a unique substance with a complex mechanism of action. It interacts with various neurotransmitter systems in the brain, including the dopaminergic system, serotonergic system, and NMDA receptors. One of its primary effects is the temporary increase of dopamine levels by inhibiting monoamine oxidase (MAO), an enzyme responsible for breaking down dopamine. This mechanism has sparked interest in its potential application for Parkinson's disease.
"Early preclinical studies and anecdotal reports suggest that ibogaine's influence on dopamine levels may offer some benefits for managing Parkinson's symptoms," said David Dardashti, founder of Ibogaine By David Dardashti. "However, it's crucial to understand that this is based on preliminary findings, and ibogaine is a powerful substance with potential risks that require thorough investigation."
"We are committed to supporting rigorous scientific research to explore the potential of ibogaine for Parkinson's and other conditions," said Dardashti. "However, it's essential to proceed with caution, prioritize patient safety, and ensure that any potential therapeutic use of ibogaine is based on sound scientific evidence."
About Ibogaine By David Dardashti
Ibogaine By David Dardashti is a leading provider of information and resources on ibogaine therapy. The organization is committed to promoting the safe and responsible use of ibogaine for the treatment of addiction and other mental health conditions, advocating for evidence-based practices and supporting research initiatives to further understand the therapeutic potential and safety profile of ibogaine.
Media Contact
Company Name: Ibogaine By David Dardashti
Contact Person: Cole Barressi
Email: Send Email
Country: United States
Website: www.ibogaineclinic.com
